Demetz, I., & Doenecke, P. (2026). Sandoz Targets $650 Billion Opportunity With Biosimilars Unit. Bloomberg.com, N.PAG.
Chicago Style (17th ed.) CitationDemetz, Isabel, and Paula Doenecke. "Sandoz Targets $650 Billion Opportunity With Biosimilars Unit." Bloomberg.com 2026: N.PAG.
MLA (9th ed.) CitationDemetz, Isabel, and Paula Doenecke. "Sandoz Targets $650 Billion Opportunity With Biosimilars Unit." Bloomberg.com, 2026, p. N.PAG.
Warning: These citations may not always be 100% accurate.